Benitec Biopharma (BNTC) Operating Leases (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Operating Leases for 7 consecutive years, with $613000.0 as the latest value for Q1 2025.
- Quarterly Operating Leases rose 888.71% to $613000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $613000.0 through Mar 2025, up 888.71% year-over-year, with the annual reading at $284000.0 for FY2024, 0.0% changed from the prior year.
- Operating Leases hit $613000.0 in Q1 2025 for Benitec Biopharma, up from $137000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $954000.0 in Q3 2021 to a low of $62000.0 in Q1 2024.
- Historically, Operating Leases has averaged $427882.4 across 5 years, with a median of $284000.0 in 2023.
- Biggest five-year swings in Operating Leases: crashed 82.49% in 2024 and later soared 888.71% in 2025.
- Year by year, Operating Leases stood at $698000.0 in 2021, then decreased by 1.86% to $685000.0 in 2022, then plummeted by 80.0% to $137000.0 in 2023, then changed by 0.0% to $137000.0 in 2024, then surged by 347.45% to $613000.0 in 2025.
- Business Quant data shows Operating Leases for BNTC at $613000.0 in Q1 2025, $137000.0 in Q4 2024, and $211000.0 in Q3 2024.